Introduction: eviQ Cancer Treatments Online is a free, web-based resource providing access to
e204 LOKE ET AL. regular formal meetings to review the information on eviQ, and the protocols are approved and published on the site only when consensus is reached. Over 600 clinicians nationally have been involved in content development and review.
Endorsed by the Council of Australian Governments as the preferred provider of cancer treatment protocols, eviQ is embedded into Australian clinical practice and policy. It is a source of information for electronic oncological record systems. Although the NSW government funds the eviQ program, each state or jurisdiction provides financial support (which includes travel expenses for interstate clinicians to participate in regular reference committee meetings for protocol and content review).
As the numbers of users and eviQ protocols increase, the priority is to ensure that eviQ remains a high-quality resource and provides credible information. In 2012, an external quality assessment of the eviQ website was conducted using the "Appraisal of Guidelines for Research and Evaluation" (AGREE-II) instrument. 1, 2 The assessment demonstrated that eviQ was generally of high quality. One of the limitations of the AGREE-II instrument is that it evaluates the methods used in guideline (or protocol) development and reporting, and not the content or evidence base supporting the recommendations (the two are not necessarily correlated).
Whilst AGREE-II ensures that robust methods are used in content development and reporting, it does not evaluate or guarantee the quality of the content or the quality perceived by its users. Perceived quality is important as it directly impacts on uptake. Users will not use eviQ if they consider the content to be substandard. Conversely, if they trust the information on eviQ, they will continue to use and promote the website. The sustainability of eviQ therefore depends on its perceived quality. The aim of this study was to examine the perceived quality of eviQ among Australian medical oncologists, the impact it had on their knowledge and practice, and the effect it had on their patients.
METHODS
Medical oncologists were selected as the target population as they are an important user group of eviQ (comprising 2666 registrants on the site) and as they represent the majority of clinical experts involved in content development and review. Medical oncology protocols comprised the majority of protocols on eviQ (365). There were also 177 protocols for hematology and bone marrow transplant, 75 protocols for cancer genetics and 70 protocols for radiation oncology. To check drug doses 26
To guide dose adjustments 22
For pre-and postmedication information (e.g. antiemetics, premedications)
17
To guide treatment administration 9
For information on side effects or toxicity 27
To guide monitoring parameters (e.g. blood tests, cardiac function)
3
To access the evidence for a given treatment 8
To give patients information 57
To guide treatment delivery in unfamiliar areas 13
For training purposes 10
For research purposes 1 respondents preferred to use eviQ. The second section (Appendix) obtained information on the quality and impact of eviQ, using questions from a validated questionnaire designed to evaluate the quality and impact of information websites, and had been previously used to assess other clinical information portals. 4 The survey included 20 items on quality and impact, classified in four domains:
1. Information quality -the currency, relevance and completeness of information in the system. 2. System quality -the organization of information in the system and its ease of use.
3.
User satisfaction -likes or dislikes and expectations of the system.
4.
Individual impact -the effectiveness of the system for users.
Answers were recorded using on a five-point Likert scale ( 
RESULTS

Characteristics of participants and their use of the eviQ website
The survey was completed by 97 of the 636 medical oncologists (including trainees) selected for this study, yielding 15% response rate.
All clinicians, with the exception of one, were practising in Australia.
Their oncology experience was <2 years for 25%, 2-10 years for 36%
and >10 years for 39%.
All of the respondents used eviQ. 56% accessed eviQ daily, 32% accessed eviQ weekly, 9% monthly and 3% rarely accessed eviQ.
eviQ was most frequently used as a source for providing patient information sheets on chemotherapy side effects, with 57% of respondents using it for this purpose on most days. Other common uses included finding information on side effects (27%), checking drug doses (26%) and guiding dose adjustments (22%).
Medical oncologists' perspectives on the quality and impact of eviQ
For questions relating to the information and system quality, participants were asked to refer to a protocol they used frequently or last accessed. The majority (>90%) of respondents agreed that the information on eviQ was of high quality, current, accurate and relevant. 38% and 66% of respondents agreed on exclusiveness (i.e. uniqueness and not available elsewhere) and completeness respectively ( Figure 1 ). With regard to system quality, 91% and 88% of respondents agreed that eviQ was easy to read, and well structured and organized respectively ( Figure 2 ).
In relation to impact, most of the respondents advocated that they provided better care and that their patients had an enhanced experience as a result of eviQ usage. Most were satisfied with eviQ and agreed that it met their expectations and fulfilled its task (Figure 3 ). 96% and 97% of respondents reported that they would visit eviQ regularly in the future and recommend it to others respectively ( Figure 4 ).
DISCUSSION
This is the first in-depth analysis of the perceived quality and impact of eviQ by Australian medical oncologists. It was found that eviQ was generally advocated by medical oncologists to be a high-quality resource that facilitated superior care. The analysis also highlighted some areas where the quality of the resource could be enhanced.
One of the areas for enhancement was the completeness of the information on eviQ. Participants were asked whether the protocols they were searching for were readily available on the website, and only 64% agreed or strongly agreed. Some of the protocols that were not found on eviQ included off-label treatments, new treatments, less common treatments and protocols for rare cancers (e.g. Ewing sarcoma).
In the rapidly changing fields of medical oncology and malignant hematology, new treatments are constantly being added to those already available. However, there is often a lag between the publication of the key trial and drug registration. In Australia, the Therapeu- Hence end users are assured that the information is regularly checked and validated. In Australia, many hospitals have resorted to electronic prescribing, using oncology management information systems such as MOSAIQ, Aria and CHARM to optimize safe chemotherapy prescribing. Although these systems reduce the need for clinicians to refer to the eviQ website, eviQ protocols are often utilized as the reference standard for developing and updating the protocols in the electronic prescribing systems and hence have been embedded in these systems.
The ultimate aim of eviQ is to improve patient outcomes. Although treatment variations and their effect on patient outcomes can be measured by analyzing data from cancer registries, patient-reported outcomes and eviQ protocols, it is an undertaking that requires substantial time and expertise. The results of this study show that eviQ can improve patient outcomes through individual practice and patient care. 93% of respondents stated that they were better informed, 82%
of respondents delivered treatments more safely and 85% of respondents thought that their patients had a better experience because of their utilization of eviQ. There was inconclusive findings as to whether eviQ assisted in making better decisions: 76% agreed and 24% was undecided or disagreed. This finding is consistent with the fact that eviQ is not designed as a clinical decision-making tool but rather, as a guidance tool on the delivery of cancer treatments after a treatment decision has been made. Areas for improving eviQ include providing more clarity on the parameters used for monitoring treatment, and on PBS information in some protocols, The need to tailor the side effects described in the patient information sheets to be more treatment-specific is also an area for improvement.
One of the strengths of this study is the use of a validated questionnaire, which has been used to evaluate other clinical information portals. The questionnaire is based on a robust conceptual model by
DeLone and McLean and has been validated by partial least squares regression. 5 The questionnaire comprehensively and reliably assesses the quality and impact of a web portal.
This study is limited by a low response rate (15%), and the results may not reflect the opinions of all Australian medical oncologists.
There may also be selection bias, in that respondents are more likely to be users and supporters of eviQ. The low response rate is, however, considered typical for oncologists, who receive many survey requests, resulting in survey fatigue. 6 This study has provided useful information, which will guide continuous quality improvements in eviQ. It will also form a baseline as eviQ undergoes a major rebuild and content review. Further research will address the quality of other content areas and perceptions by other user groups, including cancer nurses and pharmacists, hematologists, radiation oncologists and radiation therapists. Most importantly, the authors plan to seek the patient's view on the information currently provided to them on eviQ and to identify methods for improving the quality of patient information. (A) Information quality
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3) The information provided in this protocol is relevant to my practice
4) The information provided in this protocol is exclusive (i.e., unique, not available elsewhere)
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6) The protocols on eviQ are complete (i.e., the protocols I look for are always available on eviQ) 
